Twist Bioscience Projects FY2027 Revenue Between $550M and $560M
Twist Bioscience (TWST) has provided financial guidance for fiscal year 2027, forecasting revenue in the range of $550 million to $560 million. The company aims to maintain positive adjusted EBITDA as it continues its strategic expansion into AI-driven drug discovery markets. CEO Dr. Emily Leproust characterized fiscal 2026 as a pivotal year for the organization, noting accelerated top-line revenue growth and a successful transition to positive adjusted EBITDA in the fourth quarter. The company is currently focusing on scaling its technological capabilities to capture emerging opportunities in biotechnology.
Tickers: $TWST